Brokerages Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) PT at $49.94
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the twenty brokerages that are currently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and two have assigned a strong […]
More Stories
Head to Head Analysis: Iota Communications (OTCMKTS:IOTC) and Cass Information Systems (NASDAQ:CASS)
Cass Information Systems (NASDAQ:CASS – Get Free Report) and Iota Communications (OTCMKTS:IOTC – Get Free Report) are both computer and...
Short Interest in AngioDynamics, Inc. (NASDAQ:ANGO) Declines By 12.3%
AngioDynamics, Inc. (NASDAQ:ANGO – Get Free Report) was the recipient of a significant decrease in short interest during the month...
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Large Increase in Short Interest
ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) was the recipient of a large increase in short interest during...
X-Links Crude Oil Shares Covered Call ETN (NASDAQ:USOI) Short Interest Down 19.5% in December
X-Links Crude Oil Shares Covered Call ETN (NASDAQ:USOI – Get Free Report) was the target of a significant drop in...
Short Interest in Ultralife Co. (NASDAQ:ULBI) Grows By 19.3%
Ultralife Co. (NASDAQ:ULBI – Get Free Report) was the recipient of a large increase in short interest in December. As...
Tyra Biosciences, Inc. (NASDAQ:TYRA) Short Interest Up 25.9% in December
Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report) saw a significant increase in short interest in the month of December....